Application No. 10/018,963
Amendment

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula I

$$Het\text{-}A\text{-}Alk\text{-}W\text{-}Ar\text{-}C(X^2)=NO\text{-}X^1 \qquad I,$$

~~its salts, and pharmaceutically acceptable derivatives thereof where~~

~~Het is an optionally substituted 5- or 6-membered monocyclic heterocyclic radical or an optionally substituted 9- or 10-membered bicyclic heterocyclic radical, where each heterocyclic radical includes one or more heteroatoms selected from N, S and O;~~

or a salt or pharmaceutically acceptable derivative thereof, where:

Het is a radical of the formula:



(a-1),



(a-2),



(a-3),

Application No. 10/018,963
Amendment



(a-4),



(a-5),



(a-6),



(a-7),



(a-8),



(a-9),



(a-10),



(a-11),

Application No. 10/018,963
Amendment



(a-12),



(a-13) or



(a-14),

wherein each R^1 is independently selected from the group consisting of hydrogen, C_{1-6}alkyl, halo, hydroxy, mercapto, haloC_{1-4}alkyl, amino, mono (C_{1-6}alkylamino), di(C_{1-6}alkyl)amino, cyano, formyl, C_{1-6}alkoxy, hydroxyC_{1-4}alkyl, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-6} haloalkoxy, aryloxy, C_{1-6}alkylthio, arylthio, C_{1-6}alkylsulphinyl, C_{1-6} alkylsulphonyl, arylsulphinyl, arylsulphonyl, -CH=NO-C_{1-4}alkyl, C_{1-6}alkoxycarbonyl, C_{1-6}alkylcarbonyl and aryl;

R^2 and R^3 are each independently selected from the group consisting of hydrogen, C_{1-6}alkyl, C_{1-6}alkoxy and halo;

or R^1 and R^2 or R^2 and R^3 combined in radicals (a-1), (a-4), (a-7) and (a-13) may represent a bivalent radical of formula -CH=CH-CH=CH- or $(CH_2)_p$ where p is an integer from 2 to 4;

each Y is independently O or S; and

each Y' is O, S, SO or SO_2;

A is O, S, NH, N(C_{1-6} alkyl), CH_2O, a direct bond or a bivalent heterocyclic radical of the formula:



(b-1),



(b-2),



(b-3), or



(b-4),

where one or more of the carbon atoms within the radicals (b-1) to (b-4) may be optionally substituted with C_{1-6} alkyl or two carbon atoms in the radicals (b-1) to (b-4) may be bridged with a divalent C_{2-4}alkyl radical, m and n are each

independently integers of 1 to 4 inclusive with the proviso that the sum of m and n in radicals (b-1) to (b-4) is 3, 4 or 5;

Z is N or CR^6 where R^6 is hydrogen, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy or amino;

Z' is O, S, CHR^7 or NR^8 where R^7 is hydrogen, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy or amino and R^8 is hydrogen or C_{1-6} alkyl;

R^4 is hydrogen or C_{1-6} alkyl; and

R^5 is hydrogen, hydroxy, C_{1-6} alkyl or C_{1-6} alkoxy;

Alk is divalent C_{1-7}alkyl or a direct bond;

W is O, S, OCH_2, a direct bond or NR^9 where R^9 is hydrogen or C_{1-6} alkyl;

~~Ar is an optionally substituted 5- or 6-membered monocyclic aryl radical or an optionally substituted 9- or 10-membered bicyclic aryl radical;~~

Ar is a radical of the formula:



(c-1),

(c-2),



(c-3),



(c-4),



(c-5) or



(c-6),

where each Y is independently O or S; and

R^{10} and R^{11} are each independently hydrogen, C_{1-6}alkyl, hydroxy C_{1-6}alkyl, halo, amino, cyano, nitro, C_{1-6}alkoxy, hydroxy, C_{1-6}alkylthio, or trifluoromethyl;

X^1 is C_{1-6} alkyl, C_{3-6} alkenyl, C_{3-6} haloalkenyl, C_{3-6} alkynyl, C_{3-6} haloalkynyl or C_{1-6} alkyl substituted by halo, cyano, nitro, hydroxy, aryl, C_{1-4} alkoxy, C_{2-6} alkoxyalkoxy, acyl or C_{1-4} alkylthio; and

X^2 is hydrogen, cyano, F, Cl, C_{1-4} alkyl, C_{1-4} haloalkyl or a bivalent radical of formula $-(CH_2)_2-$, $-(CH_2)_3-$, $-CH_2O-$ or $-(CH_2)_2O-$ which forms a 5- or 6-membered ring with a neighbouring carbon atom of Ar;

~~wherein optional substituents for Het and Ar are selected from halo, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, haloC_{1-4}alkyl, hydroxyC_{1-4}alkyl, hydroxy, aryl, amino, cyano, mercapto, C_{1-4}alkylamino, C_{1-4}dialkylamino, aryloxy, formyl, C_{1-4}alkylcarbonyl and C_{1-4}alkoxycarbonyl;~~

with the proviso that when Alk is a direct bond and A is O, S, CH_2O or a direct bond, then W is not O, S, OCH_2 or a direct bond.

2. (Cancelled)

3. (Cancelled)

4. (Currently Amended) A compound according to ~~claim 2~~ claim 1 wherein Het is a radical of formula (a-1), (a-2) or (a-8).

5. (Currently Amended) A compound according to ~~claim 2~~ claim 1 wherein R^1 is selected from hydrogen, methyl, ethyl, chloro, methoxy and trifluoromethyl.

6. (Currently Amended) A compound according to ~~claim 2~~ claim 1 wherein R^2 and R^3 are independently hydrogen, chloro or methyl.

7. (Currently Amended) A compound according to ~~claim 2~~ claim 1 wherein Y is O or S.

8. (Original) A compound according to claim 1 wherein A is O, NH, NMe, a bond or a radical of formula (b-1).

9. (Original) A compound according to claim 1 wherein Z is CH or N.

10. (Previously presented) A compound according to claim 1 wherein Alk is divalent C_{1-6}alkyl or a direct bond.

11. (Original) A compound according to claim 1 wherein W is O.

12. (Currently Amended) A compound according to ~~claim 3~~ claim 1 wherein Ar is a radical of formula (c-1), (c-2) or (c-4).

13. (Currently Amended) A compound according to ~~claim 3~~ claim 1 wherein R^{10} and R^{11} are each independently H, methyl, chloro, hydroxy, methoxy, cyano or nitro.

14. (Currently Amended) A compound according to ~~claim 3~~ claim 1 wherein Y is O or S.

15. (Currently Amended) A compound according to claim 1 wherein X^1 is ~~selected from~~ C_{1-4}alkyl, C_{2-4}alkoxyalkyl, C_{3-4}alkenyl, C_{3-4}alkynyl, C_{1-4}haloalkyl, C_{3-4}haloalkenyl, C_{3-4}haloalkynyl or cyanomethyl.

16. (Currently Amended) A compound according to claim 1 wherein X^2 is ~~selected from~~ H, methyl or a bivalent radical of formula $(CH_2)_2$ or $(CH_2)_3$ which forms a 5- or 6-membered ring with the Ar group.

17. (Currently Amended) A compound of formula II:



II,

or a salt or pharmaceutically acceptable derivative thereof,

wherein:

R^1 is hydrogen, C_{1-4} alkyl, halo, hydroxy, mercapto, trifluoromethyl, amino, ~~mono or di(C_{1-4}alkyl)amino~~ mono(C_{1-4}alkyl)amino, di(C_{1-4}alkyl)amino, cyano, formyl, -CH=NO-C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}haloalkoxy, aryloxy, C_{1-4}alkylthio, or aryl;

Z is CH or N;

Alk is divalent C_{1-6}alkyl;

R^{10} and R^{11} are each independently hydrogen, C_{1-4}alkyl, C_{1-4}alkoxy, halo, hydroxy;

X^1 is C_{1-6} alkyl, C_{3-6} alkenyl, C_{3-6}haloalkenyl, C_{3-6} alkynyl, C_{3-6}haloalkynyl or C_{1-6}alkyl optionally substituted by halo, cyano, nitro, hydroxy, aryl, C_{1-4}alkoxy or C_{1-4}alkylthio; and

X^2 is hydrogen, cyano, C_{1-4}alkyl, C_{1-4}haloalkyl or X^2 is $-CH_2CH_2-$ or $-CH_2CH_2CH_2-$ forming a 5- or 6-membered ring with a carbon atom on the phenyl ring.

18. (Currently Amended) A compound of formula III:



III,

or a salt or pharmaceutically acceptable derivative thereof,

wherein:

R^1 is hydrogen, C_{1-4} alkyl, halo, hydroxy, mercapto, trifluoromethyl, amino, ~~mono or di(C_{1-4}alkyl)amino~~ mono(C_{1-4}alkyl)amino, di(C_{1-4}alkyl)amino, cyano, formyl, $-CH=NO-C_{1-4}$alkyl, C_{1-4}alkoxy, C_{1-4}haloalkoxy, aryloxy, C_{1-4}alkylthio, or aryl;

A is a bond or CH_2O;

Alk is divalent C_{1-7}alkyl;

R^{10} and R^{11} are each independently hydrogen, C_{1-4}alkyl, C_{1-4}alkoxy, halo, hydroxy;

X^1 is C_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}haloalkenyl, C_{3-6}alkynyl, C_{3-6}haloalkynyl or C_{1-6}alkyl optionally substituted by halo, cyano, nitro, hydroxy, aryl, C_{1-4}alkoxy or C_{1-4}alkylthio; and

X^2 is hydrogen, cyano, C_{1-4}alkyl, C_{1-4}haloalkyl or X^2 is $-CH_2CH_2-$ or $-CH_2CH_2CH_2-$ forming a 5- or 6-membered ring with a carbon atom on the phenyl ring.

19. (Currently Amended) A compound of formula IV



IV,

or a salt or pharmaceutically acceptable derivative thereof,

wherein:

R^1 is hydrogen, C_{1-4} alkyl, halo, hydroxy, mercapto, trifluoromethyl, amino, ~~mono or di(C_{1-4}alkyl)amino~~ mono(C_{1-4}alkyl)amino, di(C_{1-4}alkyl)amino, cyano, formyl, $-CH=NO-C_{1-4}$alkyl, C_{1-4} alkoxy, C_{1-4} haloalkoxy, aryloxy, C_{1-4}alkylthio, or aryl;

Z is CH or N;

Alk is divalent C_{1-6}alkyl;

R^{10} and R^{11} are each independently hydrogen, C_{1-4}alkyl, C_{1-4}alkoxy, halo, hydroxy;

X^1 is C_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}haloalkenyl, C_{3-6}alkynyl, C_{3-6}haloalkynyl or C_{1-6}alkyl optionally substituted by halo, cyano, nitro, hydroxy, aryl, C_{1-4}alkoxy or C_{1-4}alkylthio; and

X^2 is hydrogen, cyano, C_{1-4}alkyl, C_{1-4}haloalkyl or X^2 is $-CH_2CH_2-$ or $-CH_2CH_2CH_2-$ forming a 5- or 6-membered ring with a carbon atom on the phenyl ring.

20. (Currently Amended) A compound of formula V



V_a

or a salt or pharmaceutically acceptable derivative thereof,

wherein:

Het is pyridyl, pyrazinyl, thiadiazolyl, benzoxazolyl, 1,3,5-triazinyl, pyrimidinyl or quinoxalinyl, each of which may be optionally substituted with 1 to 3 substituents selected from halo, trifluoromethyl, C_{1-4}alkyl, C_{1-4}alkoxy ~~or~~ and hydroxy;

Z is CH or N;

Alk is divalent C_{1-6}alkyl;

R^{10} and R^{11} are each independently hydrogen, C_{1-4}alkyl, C_{1-4}alkoxy, halo, hydroxy;

X^1 is C_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}haloalkenyl, C_{3-6}alkynyl, C_{3-6}haloalkynyl or C_{1-6}alkyl optionally substituted by halo, cyano, nitro, hydroxy, aryl, C_{1-4}alkoxy or C_{1-4}alkylthio; and

X^2 is hydrogen, cyano, C_{1-4}alkyl, C_{1-4}haloalkyl or X^2 is $-CH_2CH_2-$ or $-CH_2CH_2CH_2-$ forming a 5- or 6-membered ring with a carbon atom on the phenyl ring.

21. (Currently Amended) A compound of formula VI

Application No. 10/018,963
Amendment



VI,

or a salt or pharmaceutically acceptable derivative thereof,

wherein:

Het is pyridyl, pyrazinyl, thiadiazolyl, benzoxazolyl, 1,3,5-triazinyl, pyrimidinyl or quinoxalinyl, each of which may be optionally substituted with 1 to 3 substituents selected from halo, trifluoromethyl, C_{1-4}alkyl, C_{1-4}alkoxy ~~or~~ and hydroxy;

A is a direct bond, O, NH or NMe;

Alk is divalent C_{1-6}alkyl;

R^{10} and R^{11} are each independently hydrogen, C_{1-4}alkyl, C_{1-4}alkoxy, halo, hydroxy;

X^1 is C_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}haloalkenyl, C_{3-6}alkynyl, C_{3-6}haloalkynyl or C_{1-6}alkyl optionally substituted by halo, cyano, nitro, hydroxy, aryl, C_{1-4}alkoxy or C_{1-4}alkylthio; and

X^2 is hydrogen, cyano, C_{1-4}alkyl, C_{1-4}haloalkyl or X^2 is $-CH_2CH_2-$ or $-CH_2CH_2CH_2-$ forming a 5- or 6-membered ring with a carbon atom on the phenyl ring.

22. (Cancelled)

23. (Original) A compound of formula VII:



VII

where A, Alk, W, Ar and X^2 are as defined in claim 1, and X^3 is X^1 or an oxime protecting group.

24. (Original) A compound of formula X

$$\text{Het-A-Alk-W-Ar-C(=NOH)}X^2 \qquad \text{X}$$

where Het, A, Alk, W, Ar and X^2 are as defined in claim 1.

25. (Currently Amended) A pharmaceutical composition comprising a compound of formula I according to claim 1, or a salt or pharmaceutically acceptable derivative thereof, ~~together with~~ and a pharmaceutically acceptable carrier.

26. (Cancelled).

27. (Currently Amended) A pharmaceutical composition comprising a compound of formula I according to claim 1, or a salt or pharmaceutically acceptable derivative thereof,

~~Het-A-Alk-W-Ar-C(X^2)=NO-X^1 I~~

~~a salt thereof or a pharmaceutically acceptable derivative thereof where~~

~~Het is an optionally substituted 5- or 6-membered monocyclic heterocyclic radical or an optionally substituted 9- or 10-membered bicyclic heterocyclic radical, where each heterocyclic radical includes one or more heteroatoms selected from N, S and O;~~

~~A is O, S, NH, N(C_{1-6}alkyl), CH_2O, a direct bond or a bivalent heterocyclic radical of the formula~~



~~(b-1)~~



~~(b-2),~~



~~(b-3), or~~



~~(b-4)~~

~~where one or more of the carbon atoms within the radicals (b-1) to (b-4) may be optionally substituted with C_{1-4}alkyl or two carbon atoms in the radicals (b-1) to (b-4) may be bridged with a divalent C_{2-4}alkyl radical, m and n are each independently integers of 1 to 4 inclusive with the proviso that the sum of m and n in radicals (b-1) to (b-4) is 3, 4 or 5;~~

~~Z is N or CR^6 where R^6 is hydrogen, hydroxy, C_{1-6}alkyl, C_{1-6}alkoxy or amino;~~

~~Z' is O, S, CHR^7 or NR^8 where R^7 is hydrogen, hydroxy, C_{1-6}alkyl, C_{1-6}alkoxy or amino and R^8 is hydrogen or C_{1-6}alkyl;~~

~~R^4 is hydrogen or C_{1-6}alkyl; and~~

~~R^5 is hydrogen, hydroxy, C_{1-6}alkyl or C_{1-6}alkoxy;~~

~~Alk is divalent C_{1-7}alkyl or a direct bond;~~

~~W is O, S, OCH_2, a direct bond or NR^9 where R^9 is hydrogen or C_{1-6}alkyl;~~

~~Ar is an optionally substituted 5- or 6-membered monocyclic aryl radical or an optionally substituted 9- or 10-membered bicyclic aryl radical;~~

~~X^1 is C_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}haloalkenyl, C_{3-6}alkynyl, C_{3-6}haloalkynyl or C_{1-6}alkyl substituted by halo, cyano, nitro, hydroxy, aryl, C_{1-4}alkoxy, C_{2-6}alkoxyalkoxy, acyl or C_{1-4}alkylthio; and~~

~~X^2 is hydrogen, cyano, F, Cl, C_{1-4}alkyl, C_{1-4}haloalkyl or a bivalent radical of formula $-(CH_2)_2-$, $-(CH_2)_3-$, $-CH_2O-$ or $-(CH_2)_2O-$ which forms a 5- or 6-membered ring with a neighbouring carbon atom of Ar;~~

~~wherein optional substituents for Het and Ar are selected from halo, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, haloC_{1-4}alkyl, hydroxyC_{1-4}alkyl, hydroxy, aryl, amino, cyano, mercapto, C_{1-4}alkylamino, C_{1-4}dialkylamino, aryloxy, formyl, C_{1-4}alkylcarbonyl and C_{1-4}alkoxycarbonyl;~~

a pharmaceutically acceptable carrier and ~~further including~~ a known anti-viral or anti-retroviral agent or other pharmaceutical ~~used in the treatment of viral infections~~.

Application No. 10/018,963
Amendment

28. (Currently Amended) A method for the treatment ~~or prophylaxis~~ of a picornavirus infection in a mammal including the step of administering an effective amount of a compound of formula I according to claim 1, or a salt or pharmaceutically acceptable derivative thereof.

~~Het-A-Alk-W-Ar-C(X^2)=NO-X^1 I~~

~~a salt thereof or a and pharmaceutically acceptable derivative thereof. where~~

~~Het is an optionally substituted 5- or 6-membered monocyclic heterocyclic radical or an optionally substituted 9- or 10-membered bicyclic heterocyclic radical, where each heterocyclic radical includes one or more heteroatoms selected from N, S and O;~~

~~A is O, S, NH, N(C_{1-6}alkyl), CH_2O, a direct bond or a bivalent heterocyclic radical of the formula~~



~~(b-1)~~



~~(b-2),~~



~~(b-3), or~~



~~(b-4)~~

~~where one or more of the carbon atoms within the radicals (b-1) to (b-4) may be optionally substituted with C_{1-6}alkyl or two carbon atoms in the radicals (b-1) to (b-4) may be bridged with a divalent C_{2-4}alkyl radical, m and n are each independently integers of 1 to 4 inclusive with the proviso that the sum of m and n in radicals (b-1) to (b-4) is 3, 4 or 5;~~

~~Z is N or CR^6 where R^6 is hydrogen, hydroxy, C_{1-6}alkyl, C_{1-6}alkoxy or amino;~~

~~Z' is O, S, CHR^7 or NR^8 where R^7 is hydrogen, hydroxy, C_{1-6}alkyl, C_{1-6}alkoxy or amino and R^8 is hydrogen or C_{1-6}alkyl;~~

~~R^4 is hydrogen or C_{1-6}alkyl; and~~

~~R^5 is hydrogen, hydroxy, C_{1-6}alkyl or C_{1-6}alkoxy;~~

~~Alk is divalent C_{1-7}alkyl or a direct bond;~~

~~W is O, S, OCH_2, a direct bond or NR^9 where R^9 is hydrogen or C_{1-6}alkyl;~~

~~Ar is an optionally substituted 5- or 6-membered monocyclic aryl radical or an optionally substituted 9- or 10-membered bicyclic aryl radical;~~

~~X^1 is C_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}haloalkenyl, C_{3-6}alkynyl, C_{3-6}haloalkynyl or C_{1-6}alkyl substituted by halo, cyano, nitro, hydroxy, aryl, C_{1-4}alkoxy, C_{2-6}alkoxyalkoxy, acyl or C_{1-4}alkylthio; and~~

~~X^2 is hydrogen, cyano, F, Cl, C_{1-4}alkyl, C_{1-4}haloalkyl or a bivalent radical of formula $-(CH_2)_2-$, $-(CH_2)_3-$, $-CH_2O-$ or $-(CH_2)_2O-$ which forms a 5- or 6-membered ring with a neighbouring carbon atom of Ar;~~

~~wherein optional substituents for Het and Ar are selected from halo, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, haloC_{1-4}alkyl, hydroxyC_{1-4}alkyl, hydroxy, aryl, amino, cyano, mercapto, C_{1-4}alkylamino, C_{1-4}dialkylamino, aryloxy, formyl, C_{1-4}alkylcarbonyl and C_{1-4}alkoxycarbonyl.~~

29. (Original) A method of claim 27 wherein the picornaviral infection is caused by one or more serotypes of rhinovirus.

30. (Currently Amended) A method for preparing a pharmaceutical composition comprising admixing a compound of formula I according to claim 1, or a salt or pharmaceutically acceptable derivative thereof;

~~Het-A-Alk-W-Ar-C(X^2)=NO-X^1 I~~

~~a salt thereof or a pharmaceutically acceptable derivative thereof where~~

~~Het is an optionally substituted 5- or 6-membered monocyclic heterocyclic radical or an optionally substituted 9- or 10-membered bicyclic heterocyclic radical, where each heterocyclic radical includes one or more heteroatoms selected from N, S and O;~~

~~A is O, S, NH, N(C_{1-6}alkyl), CH_2O, a direct bond or a bivalent heterocyclic radical of the formula~~



~~(b-1)~~



~~(b-2),~~



~~(b-3), or~~



~~(b-4)~~

~~where one or more of the carbon atoms within the radicals (b-1) to (b-4) may be optionally substituted with C_{1-6}alkyl or two carbon atoms in the radicals (b-1) to (b-4) may be bridged with a C_{2-4} alkylene divalent C_{2-4}alkyl radical, m and n are each~~

~~independently integers of 1 to 4 inclusive with the proviso that the sum of m and n in radicals (b-1) to (b-4) is 3, 4 or 5;~~

~~Z is N or CR^6 where R^6 is hydrogen, hydroxy, C_{1-6}alkyl, C_{1-6}alkoxy or amino;~~

~~Z' is O, S, CHR^7 or NR^8 where R^7 is hydrogen, hydroxy, C_{1-6}alkyl, C_{1-6}alkoxy or amino and R^8 is hydrogen or C_{1-6}alkyl;~~

~~R^4 is hydrogen or C_{1-6}alkyl; and~~

~~R^5 is hydrogen, hydroxy, C_{1-6}alkyl or C_{1-6}alkoxy;~~

~~Alk is divalent C_{1-7}alkyl or a direct bond;~~

~~W is O, S, OCH_2, a direct bond or NR^9 where R^9 is hydrogen or C_{1-6}alkyl;~~

~~Ar is an optionally substituted 5- or 6-membered monocyclic aryl radical or an optionally substituted 9- or 10-membered bicyclic aryl radical;~~

~~X^1 is C_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}haloalkenyl, C_{3-6}alkynyl, C_{3-6}haloalkynyl or C_{1-6}alkyl substituted by halo, cyano, nitro, hydroxy, aryl, C_{1-4}alkoxy, C_{2-6}alkoxyalkoxy, acyl or C_{1-4}alkylthio; and~~

~~X^2 is hydrogen, cyano, F, Cl, C_{1-4}alkyl, C_{1-4}haloalkyl or a bivalent radical of formula $-(CH_2)_2-$, $-(CH_2)_3-$, $-CH_2O-$ or $-(CH_2)_2O-$ which forms a 5- or 6-membered ring with a neighbouring carbon atom of Ar;~~

~~wherein optional substituents for Het and Ar are selected from halo, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, haloC_{1-4}alkyl, hydroxyC_{1-4}alkyl, hydroxy, aryl, amino, cyano, mercapto, C_{1-4}alkylamino, C_{1-4}dialkylamino, aryloxy, formyl, C_{1-4}alkylcarbonyl and C_{1-4}alkoxycarbonyl;~~

with one or more pharmaceutically acceptable carriers therefore.

31. (Cancelled)

32. (Previously Presented)A compound selected from the group consisting of the following:

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

1-(4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-phenyl)-ethanone *O*-ethyl-oxime;

1-(4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-phenyl)-ethanone *O*-ethyl-oxime;

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-3-methoxy-benzaldehyde *O*-ethyl-oxime;

1-(4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-3,5-dimethoxy-phenyl)-ethanone *O*-ethyl-oxime;

4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;

1-(4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-phenyl)-ethanone *O*-methyl-oxime;

1-(4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-phenyl)-propan-1-one *O*-methyl-oxime;

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-propyl-oxime;

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-isopropyl-oxime;

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-allyl-oxime;

[1-(4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-phenyl)-meth-(E)-ylideneaminooxy]-acetonitrile;

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-benzyl-oxime;

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-3,5-dimethyl-benzaldehyde *O*-methyl-oxime;

1-(4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-3-methoxy-phenyl)-ethanone *O*-methyl-oxime;

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-[2-(2-ethoxy-ethoxy)-ethyl]-oxime;

4-(2-{1-[6-(2,2,2-Trifluoro-ethoxy)-pyridazin-3-yl]-piperidin-4-yl}-ethoxy)-benzaldehyde *O*-ethyl-oxime;

4-{2-[1-(6-Methoxy-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

4-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-ylmethoxy]-benzaldehyde *O*-benzyl-oxime;

4-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-ylmethoxy]-benzaldehyde *O*-allyl-oxime;

4-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-ylmethoxy]-benzaldehyde *O*-ethyl-oxime;

4-{3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-propoxy}-benzaldehyde *O*-ethyl-oxime;

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-3-methoxy-benzaldehyde *O*-methyl-oxime;

1-(4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-phenyl)-propan-1-one *O*-ethyl-oxime;

1-(4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-phenyl)-propan-1-one *O*-allyl-oxime;

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-3-nitro-benzaldehyde *O*-ethyl-oxime;

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-2-hydroxy-benzaldehyde *O*-ethyl-oxime;

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-3-methyl-benzaldehyde *O*-ethyl-oxime;

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-3-methyl-benzaldehyde *O*-allyl-oxime;

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-3-methyl-benzaldehyde *O*-methyl-oxime;

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-3,5-dimethyl-benzaldehyde *O*-ethyl-oxime;

4-[2-(1-Pyridazin-3-yl-piperidin-4-yl)-ethoxy]-benzaldehyde *O*-ethyl-oxime;

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-2-methoxy-benzaldehyde *O*-ethyl-oxime;

3-Methyl-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

3-Methyl-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;

3-Methyl-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-allyl-oxime;

3-Methyl-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-propyl-oxime;

4-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yloxy]-benzaldehyde *O*-ethyl-oxime;

4-{2-[1-(6-Phenyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

(Z)-4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

4-{2-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-(2,2,2-trifluoro-ethyl)-oxime;

4-{2-[1-(6-Methoxy-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-allyl-oxime;

4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-propyl-oxime;

4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-(2-methoxy-ethyl)-oxime;

4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-allyl-oxime;

4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-prop-2-ynyl-oxime;

4-{3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-propoxy}-benzaldehyde *O*-methyl-oxime;

4-{3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-propoxy}-benzaldehyde *O*-allyl-oxime;

4-{3-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-propoxy}-benzaldehyde *O*-methyl-oxime;

4-{3-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-propoxy}-benzaldehyde *O*-ethyl-oxime;

4-{3-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-propoxy}-benzaldehyde *O*-allyl-oxime;

4-{3-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-4-yl]-propoxy}-benzaldehyde *O*-methyl-oxime;

4-[3-(1-Pyridazin-3-yl-piperidin-4-yl)-propoxy]-benzaldehyde *O*-methyl-oxime;

4-[3-(1-Pyridazin-3-yl-piperidin-4-yl)-propoxy]-benzaldehyde *O*-ethyl-oxime;

4-[3-(1-Pyridazin-3-yl-piperidin-4-yl)-propoxy]-benzaldehyde *O*-allyl-oxime;

6-(4-{2-[4-(Ethoxyimino-methyl)-phenoxy]-ethyl}-piperidin-1-yl)-pyridazine-3-carbaldehyde;

4-{2-[1-(6-Hydroxymethyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-(2-fluoro-ethyl)-oxime;

4-{2-[1-(6-Methyl-2-oxy-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

3-Hydroxy-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

2,6-Dimethyl-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

2,6-Dimethyl-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;

2-Methoxy-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

2-Methyl-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

2-Methyl-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;

2,5-Dimethyl-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

2,5-Dimethyl-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;

2,3-Dimethyl-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

2,3-Dimethyl-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime; and

6-(4-{2-[4-(Ethoxyimino-methyl)-phenoxy]-ethyl}-piperidin-1-yl)-pyridazine-3-carbaldehyde *O*-methyl-oxime.

33. (Previously Presented) A compound selected from the group consisting of the following:

3-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;

3-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-4-methoxy-benzaldehyde *O*-methyl-oxime;

3-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-5-hydroxy-benzaldehyde *O*-methyl-oxime;

3-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-5-hydroxy-benzaldehyde *O*-ethyl-oxime;

3-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-5-hydroxy-benzaldehyde *O*-allyl-oxime;

3-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

3-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

3-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-allyl-oxime;

3-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;

3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-ylmethoxy]-benzaldehyde *O*-methyl-oxime;

3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-ylmethoxy]-benzaldehyde *O*-ethyl-oxime;

3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-ylmethoxy]-benzaldehyde *O*-allyl-oxime;

3-{3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-propoxy}-benzaldehyde *O*-methyl-oxime;

3-{3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-propoxy}-benzaldehyde *O*-ethyl-oxime;

3-{3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-propoxy}-benzaldehyde *O*-allyl-oxime;

3-{3-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-propoxy}-benzaldehyde *O*-methyl-oxime;

3-{3-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-propoxy}-benzaldehyde *O*-ethyl-oxime;

3-{3-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-propoxy}-benzaldehyde *O*-allyl-oxime;

3-{3-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-4-yl]-propoxy}-benzaldehyde *O*-methyl-oxime;

3-[3-(1-Pyridazin-3-yl-piperidin-4-yl)-propoxy]-benzaldehyde *O*-methyl-oxime;

3-[3-(1-Pyridazin-3-yl-piperidin-4-yl)-propoxy]-benzaldehyde *O*-ethyl-oxime;

3-[3-(1-Pyridazin-3-yl-piperidin-4-yl)-propoxy]-benzaldehyde *O*-allyl-oxime; and

4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-indan-1-one *O*-ethyl-oxime.

34. (Currently Amended) A compound selected from the group consisting of the following: ~~wherein the compound is selected from the group consisting of the following:~~

3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-benzaldehyde *O*-methyl-oxime;

3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-benzaldehyde *O*-allyl-oxime;

3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-benzaldehyde *O*-ethyl-oxime;

3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-benzaldehyde *O*-benzyl-oxime;

4-[3-(3-Methyl-isoxazol-5-yl)-propoxy]-benzaldehyde *O*-ethyl-oxime;

1-{3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-phenyl}-ethanone *O*-methyl-oxime;

1-{3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-phenyl}-ethanone *O*-allyl-oxime;

1-{3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-phenyl}-ethanone *O*-allyl-oxime;

3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-benzaldehyde *O*-propyl-oxime;

1-{3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-phenyl}-propan-1-one *O*-methyl-oxime;

1-{3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-phenyl}-propan-1-one *O*-ethyl-oxime;

1-{3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-phenyl}-propan-1-one *O*-allyl-oxime;

1-{3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-phenyl}-ethanone *O*-ethyl-oxime;

3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-benzaldehyde *O*-isopropyl-oxime;

[1-{3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-phenyl}-meth-(E)-ylideneaminooxy]-acetonitrile;

3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-benzaldehyde *O*-prop-2-ynyl-oxime;

3,5-Dimethyl-4-[6-(3-methyl-isoxazol-5-yl)-hexyloxy]-benzaldehyde *O*-ethyl-oxime;

3,5-Dimethyl-4-[7-(3-methyl-isoxazol-5-yl)-heptyloxy]-benzaldehyde *O*-ethyl-oxime;

3,5-Dimethyl-4-[5-(3-methyl-isoxazol-5-yl)-pentyloxy]-benzaldehyde *O*-ethyl-oxime;

3,5-Dimethyl-4-[4-(3-methyl-isoxazol-5-yl)-butoxy]-benzaldehyde *O*-ethyl-oxime;

3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-benzaldehyde *O*-(2,2,2-trifluoro-ethyl)-oxime;

3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-benzaldehyde *O*-(2-ethoxy-ethyl)-oxime;

3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-benzaldehyde *O*-(2-oxo-propyl)-oxime;

3,5-Dimethyl-4-[3-(3-phenyl-isoxazol-5-yl)-propoxy]-benzaldehyde *O*-ethyl-oxime;

4-[3-(3-Ethyl-isoxazol-5-yl)-propoxy]-3,5-dimethyl-benzaldehyde *O*-ethyl-oxime;

3,5-Dimethyl-4-[3-(3-propyl-isoxazol-5-yl)-propoxy]-benzaldehyde *O*-ethyl-oxime;

4-[2-(3-Ethyl-isoxazol-5-yl)-ethoxy]-3,5-dimethyl-benzaldehyde *O*-ethyl-oxime;

3-Methyl-4-[2-(3-propyl-isoxazol-5-yl)-ethoxy]-benzaldehyde *O*-ethyl-oxime;

3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-benzaldehyde *O*-(2-fluoro-ethyl)-oxime;

4-[3-(3-Cyclopropyl-isoxazol-5-yl)-propoxy]-3,5-dimethyl-benzaldehyde *O*-ethyl-oxime;

4-[4-(3-Ethyl-isoxazol-5-yl)-butoxy]-3,5-dimethyl-benzaldehyde *O*-ethyl-oxime; and

3,5-Dimethyl-4-[4-(3-propyl-isoxazol-5-yl)-butoxy]-benzaldehyde *O*-ethyl-oxime.

35. (Previously Presented) A compound selected from the group consisting of the following:

4-{2-[4-(6-Chloro-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

4-[2-(4-Pyridazin-3-yl-piperazin-1-yl)-ethoxy]-benzaldehyde *O*-ethyl-oxime;

3-[2-(4-Pyridazin-3-yl-piperazin-1-yl)-ethoxy]-benzaldehyde *O*-ethyl-oxime;

4-[2-(4-Pyridazin-3-yl-piperazin-1-yl)-ethoxy]-benzaldehyde *O*-allyl-oxime;

4-{2-[4-(6-Methyl-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;

4-{2-[4-(6-Methyl-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

4-{2-[4-(6-Methyl-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-allyl-oxime;

3-{2-[4-(6-Methyl-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;

3-{2-[4-(6-Methyl-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

3-{2-[4-(6-Methyl-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-allyl-oxime;

4-{2-[4-(6-Chloro-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;

4-{2-[4-(6-Chloro-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-allyl-oxime;

3-{2-[4-(6-Chloro-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;

3-{2-[4-(6-Chloro-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

3-{2-[4-(6-Chloro-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-allyl-oxime;

4-{2-[4-(6-Trifluoromethyl-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;

4-{2-[4-(6-Trifluoromethyl-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

4-{2-[4-(6-Trifluoromethyl-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-allyl-oxime;

3-{2-[4-(6-Trifluoromethyl-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;

3-{2-[4-(6-Trifluoromethyl-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

3-{2-[4-(6-Trifluoromethyl-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-allyl-oxime;

4-{2-[4-(6-Methyl-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-propyl-oxime;

3-{2-[4-(6-Methyl-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-propyl-oxime;

4-{2-[4-(6-Chloro-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-propyl-oxime; and

3-{2-[4-(6-Chloro-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-propyl-oxime.

36. (Previously Presented) A compound selected from the group consisting of the following:

4-[1-(6-Chloro-pyridazin-3-yl)-piperidin-3-ylmethoxy]-benzaldehyde *O*-ethyl-oxime;

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-3-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-3-yl]-ethoxy}-benzaldehyde *O*-allyl-oxime;

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-3-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

4-{3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-3-yl]-propoxy}-benzaldehyde *O*-ethyl-oxime;

4-{3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-3-yl]-propoxy}-benzaldehyde *O*-allyl-oxime;

4-{3-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-3-yl]-propoxy}-benzaldehyde *O*-methyl-oxime;

4-{3-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-3-yl]-propoxy}-benzaldehyde *O*-ethyl-oxime;

4-{3-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-3-yl]-propoxy}-benzaldehyde *O*-allyl-oxime;

3-{3-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-3-yl]-propoxy}-benzaldehyde *O*-methyl-oxime;

3-{3-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-3-yl]-propoxy}-benzaldehyde *O*-ethyl-oxime;

3-{3-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-3-yl]-propoxy}-benzaldehyde *O*-allyl-oxime;

4-{3-[1-(6-Methyl-pyridazin-3-yl)-piperidin-3-yl]-propoxy}-benzaldehyde *O*-allyl-oxime;

3-{3-[1-(6-Methyl-pyridazin-3-yl)-piperidin-3-yl]-propoxy}-benzaldehyde *O*-methyl-oxime;

3-{3-[1-(6-Methyl-pyridazin-3-yl)-piperidin-3-yl]-propoxy}-benzaldehyde *O*-ethyl-oxime;

3-{3-[1-(6-Methyl-pyridazin-3-yl)-piperidin-3-yl]-propoxy}-benzaldehyde *O*-allyl-oxime;

4-[1-(6-Chloro-pyridazin-3-yl)-piperidin-3-ylmethoxy]-benzaldehyde *O*-methyl-oxime;

4-[1-(6-Chloro-pyridazin-3-yl)-piperidin-3-ylmethoxy]-benzaldehyde *O*-allyl-oxime;

3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-3-ylmethoxy]-benzaldehyde *O*-methyl-oxime;

3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-3-ylmethoxy]-benzaldehyde *O*-ethyl-oxime;

3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-3-ylmethoxy]-benzaldehyde *O*-allyl-oxime;

4-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-3-ylmethoxy]-benzaldehyde *O*-methyl-oxime;

4-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-3-ylmethoxy]-benzaldehyde *O*-ethyl-oxime;

4-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-3-ylmethoxy]-benzaldehyde *O*-allyl-oxime;

3-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-3-ylmethoxy]-benzaldehyde *O*-methyl-oxime;

3-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-3-ylmethoxy]-benzaldehyde *O*-ethyl-oxime; and

3-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-3-ylmethoxy]-benzaldehyde *O*-allyl-oxime.

37. (Previously Presented) A compound selected from the group consisting of the following:

4-[2-(5'-Trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-ethoxy]-benzaldehyde *O*-ethyl-oxime;

4-[2-(5'-Chloro-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl)-ethoxy]-benzaldehyde *O*-ethyl-oxime;

4-{2-[1-(5-Trifluoromethyl-[1,3,4]thiadiazol-2-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;

4-{2-[1-(5-Trifluoromethyl-[1,3,4]thiadiazol-2-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

4-{2-[1-(5-Methyl-[1,3,4]thiadiazol-2-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;

4-{2-[1-(5-Methyl-[1,3,4]thiadiazol-2-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

4-{2-[1-(5-Chloro-pyrazin-2-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;

4-{2-[1-(5-Chloro-pyrazin-2-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

4-[2-(6'-Methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-ethoxy]-benzaldehyde *O*-ethyl-oxime;

2-(4-{2-[4-(Methoxyimino-methyl)-phenoxy]-ethyl}-piperidin-1-yl)-thiazole-4-carboxylic acid ethyl ester;

2-(4-{2-[4-(Ethoxyimino-methyl)-phenoxy]-ethyl}-piperidin-1-yl)-thiazole-4-carboxylic acid ethyl ester;

4-{2-[1-(6-Chloro-pyrazin-2-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;

4-[2-(1-Benzooxazol-2-yl-piperidin-4-yl)-ethoxy]-benzaldehyde *O*-methyl-oxime;

4-[2-(1-Benzooxazol-2-yl-piperidin-4-yl)-ethoxy]-benzaldehyde *O*-ethyl-oxime;

4-{2-[1-(4,6-Dimethoxy-[1,3,5]triazin-2-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;

4-{2-[1-(4,6-Dimethoxy-[1,3,5]triazin-2-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

4-{2-[1-(5-Ethyl-pyrimidin-2-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;

4-{2-[1-(5-Ethyl-pyrimidin-2-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

4-[2-(1-Benzothiazol-2-yl-piperidin-4-yl)-ethoxy]-benzaldehyde *O*-methyl-oxime;

4-[2-(1-Benzothiazol-2-yl-piperidin-4-yl)-ethoxy]-benzaldehyde *O*-ethyl-oxime;

4-{2-[1-(6-Chloro-quinoxalin-2-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime; and

4-{2-[1-(6-Chloro-5-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime.

38. (Currently Amended) A compound selected from the group consisting of the following:

4-[5-(6-Chloro-pyridazin-3-ylamino)-pentyloxy]-benzaldehyde *O*-ethyl-oxime;

4-{5-[(6-Chloro-pyridazin-3-yl)-methyl-amino]-pentyloxy}-benzaldehyde *O*-ethyl-oxime;

4-[6-(6-Chloro-pyridazin-3-ylamino)-hexyloxy]-benzaldehyde *O*-ethyl-oxime;

4-[4-(6-Chloro-pyridazin-3-ylamino)-butoxy]-benzaldehyde *O*-ethyl-oxime;

4-{6-[(6-Chloro-pyridazin-3-yl)-methyl-amino]-hexyloxy}-benzaldehyde *O*-methyl-oxime;

4-{4-[(6-Chloro-pyridazin-3-yl)-methyl-amino]-butoxy}-benzaldehyde *O*-ethyl-oxime;

4-[5-(6-Chloro-pyridazin-3-yloxy)-pentyloxy]-benzaldehyde *O*-ethyl-oxime; and

4-(6-Chloro-quinoxalin-2-yloxy)-benzaldehyde *O*-ethyl-oxime.

39. (Currently Amended) A compound selected from the group consisting of the following:

2-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-thiazole-4-carbaldehyde *O*-ethyl-oxime; and

2-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-thiazole-4-carbaldehyde *O*-methyl-oxime.